尽管肥胖是子宫内膜上皮内瘤变 (EIN) 和子宫癌的重要危险因素，但对于患有 EIN 和子宫癌的肥胖患者使用减肥疗法的趋势知之甚少。我们研究了减肥疗法在患有 EIN 和子宫癌的肥胖患者中的使用情况。Merative MarketScan 数据库用于识别 18-70 岁的肥胖并诊断患有 EIN 或子宫癌的患者。 EIN 或子宫癌的主要治疗方法分为初次子宫切除术或激素治疗。营养咨询、减肥手术和体重管理药物被认为是减肥疗法。我们通过 Cochran-Armitage 测试分析了任何减肥疗法的使用趋势。开发了多变量逻辑回归模型来检查与减肥治疗使用相关的因素。总共确定了 15,374 名患者，其中包括 5561 名 (36.2%) 患有 EIN 和肥胖的患者，以及 9813 名 (63.8%) 患有子宫癌和肥胖的患者。诊断后 1 年内，480 名 (8.6%) 的 EIN 患者和 802 名 (8.2%) 的子宫癌患者接受了减肥治疗。 EIN 诊断后使用任何减肥疗法的比例从 2009 年的 4.1% 增加到 2020 年的 12.6% (P < .001)，子宫癌诊断后使用任何减肥疗法的比例从 2009 年的 4.9% 增加到 2020 年。 2020 年为 11.4% (P < .001)。在多变量回归模型中，年龄较小和合并症评分较高的患者与使用任何减肥疗法的可能性较高相关。减肥疗法的使用有所增加，但患者中这种辅助疗法的使用仍然严重不足患有肥胖症、EIN 或子宫癌。版权所有 © 2024 Elsevier Inc. 保留所有权利。

Although obesity is an important risk factor for endometrial intraepithelial neoplasia (EIN) and uterine cancer, little is known about the trends in use of weight-loss therapy for patients with obesity with EIN and uterine cancer. We examined the use of weight-loss therapy among patients with obesity with EIN and uterine cancer.The Merative MarketScan Database was used to identify patients aged 18-70 years who were obese and diagnosed with EIN or uterine cancer. The primary treatment for EIN or uterine cancer was categorized as either primary hysterectomy or hormonal therapy. Nutrition counseling, bariatric surgeries, and weight-management medications were identified as weight-loss therapy. We analyzed trends in the use of any weight-loss therapies with Cochran-Armitage tests. A multivariable logistic regression model was developed to examine factors associated with weight-loss therapy use.Overall, 15,374 patients were identified, including 5561 (36.2%) patients with EIN and obesity, and 9813 (63.8%) patients with uterine cancer and obesity. Weight-loss therapy was utilized within 1 year after diagnosis in 480 (8.6%) patients with EIN and in 802 (8.2%) patients with uterine cancer. Use of any weight-loss therapy after diagnosis of EIN increased from 4.1% in 2009 to 12.6% in 2020 (P < .001), and the use of any weight-loss therapy after diagnosis of uterine cancer increased from 4.9% in 2009 to 11.4% in 2020 (P < .001). In a multivariable regression model, younger age and patients with high comorbidity score were associated with a higher likelihood of using any weight-loss therapy.Use of weight-loss therapy has increased, however there is still a significant underuse of this adjunctive therapy in patients with obesity with EIN or uterine cancer.Copyright © 2024 Elsevier Inc. All rights reserved.